Analyst Ratings for Regeneron Pharma (REGN) [Neutrals]
REGN Rating Summary
REGN Price Target Summary
- Highest: $315.00 (Brean Capital)
- Lowest: $60.00 (Needham & Company)
- Average: $163.53
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$163.53 (-29.7%)
Avg. $ Target:
$163.53 (-29.7%)
| Date | Firm | Type | Rating (Past) |
PT (Past) |
Start $ | End $ | % Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/17/2013 | UBS | New Coverage | Neutral (N/A) |
290.00 (N/A) |
264.66 | 232.71 | -12.07% | Details |
| 1/15/2013 | Jefferies | Downgrade | Hold (Buy) |
179.00 (179.00) |
179.40 | 232.71 | 29.72% | Details |
| 8/7/2012 | Lazard Capital | New Coverage | Neutral (N/A) |
N/A (N/A) |
137.45 | 232.71 | 69.31% | Details |
| 2/6/2012 | Piper Jaffray | Downgrade | Neutral (N/A) |
81.00 (N/A) |
4.14 | 232.71 | 5521.01% | Details |
| 1/17/2012 | Roth Capital | Downgrade | Neutral (N/A) |
78.00 (N/A) |
78.92 | 232.71 | 194.87% | Details |
| 10/4/2011 | JPMorgan | New Coverage | Neutral (N/A) |
60.00 (N/A) |
55.43 | 232.71 | 319.83% | Details |
| 8/26/2011 | Citi » Updated 2/6/2012 |
Downgrade | Neutral (N/A) |
68.00 (N/A) |
56.29 | 232.71 | 313.41% | Details |
| 4/28/2011 | Boenning & Scattergood | Downgrade | Neutral (N/A) |
N/A (N/A) |
67.05 | 232.71 | 247.07% | Details |
| 2/23/2011 | Stifel Nicolaus | New Coverage | Hold (N/A) |
N/A (N/A) |
36.61 | 232.71 | 535.65% | Details |
| 12/16/2010 | MP Advisors | Downgrade | Market Perform (N/A) |
N/A (N/A) |
32.22 | 232.71 | 622.25% | Details |
| 10/15/2010 | Cowen | New Coverage | Neutral (N/A) |
N/A (N/A) |
28.25 | 232.71 | 723.75% | Details |
